Given that this kinase is also required for the differentiation of naïve CD4+ T cells into Th17 effector cells, Casein Kinase 2 may serve as a therapeutic target for the treatment of inflammatory diseases including multiple sclerosis and inflammatory bowel disease. Here, CD4 is linked to inflammatory bowel disease.